Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anatomic Stage III Breast Cancer AJCC v8: early-phase trial registry
48 of 85 indexed Anatomic Stage III Breast Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #165 of 28,707 conditions by registered trial count.
85 US clinical trials · 48 currently recruiting · #165 of 28,707 conditions by registered trial count
Anatomic Stage III Breast Cancer AJCC v8: 85 US clinical trials tracked, 48 recruiting.
Anatomic Stage III Breast Cancer AJCC v8 is the subject of 85 registered US clinical trials on ClinicalTrials.gov, 48 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 14 of these trials.
Enrollment posture brief
Registry condition anatomic-stage-iii-breast-cancer-ajcc-v8
OPEN 48 | RECR 56% | LATE 8 | EARLY 43 | RANK #165 | SPON 14
Volume-matched condition peers
Nearest open-share peer: MDS (57% recruiting · 23 trials)
Anatomic Stage III Breast Cancer AJCC v8 lists 48 open slots (56% of 85 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anatomic Stage III Breast Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anatomic Stage III Breast Cancer AJCC v8 is recruiting above its size-band peers.
48 of 85 indexed trials (56.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anatomic Stage III Breast Cancer AJCC v8 research.
National Cancer Institute (NCI) accounts for 14 of 85 trials (16.5%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical Anatomic Stage III Breast Cancer AJCC v8 enrolment sits around 60 participants.
Median target enrolment is 60 among the 85 trials that report a genuine target (sentinel values excluded). 50 of those (58.8%) plan for fewer than 100 participants.
-
Anatomic Stage III Breast Cancer AJCC v8 research is mostly interventional.
77 interventional and 8 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
85 total, page 2 of 2
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Alliance for Clinical Trials in Oncology
NCT04379570
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01334021
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Alliance for Clinical Trials in Oncology
NCT04457596
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
NCT02115282
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
SWOG Cancer Research Network
NCT05568472
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Alliance for Clinical Trials in Oncology
NCT04549571
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT04906200
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
Thomas Jefferson University
NCT04086875
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
M.D. Anderson Cancer Center
NCT04754412
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
ECOG-ACRIN Cancer Research Group
NCT04001829
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
ECOG-ACRIN Cancer Research Group
NCT05710328
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
Mayo Clinic
NCT04443413
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT05049746
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
NCT02849496
Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT03786354
A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors
University of Washington
NCT06392789
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02453620
Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial
Fred Hutchinson Cancer Center
NCT06643455
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
University of Washington
NCT05455658
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
NCT06630325
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
M.D. Anderson Cancer Center
NCT05025059
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
NCT04345913
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT03218826
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT04673448
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
NCT03179904
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
NCT03941730
Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer
M.D. Anderson Cancer Center
NCT00507923
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
Ohio State University Comprehensive Cancer Center
NCT04862585
An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors
Ohio State University Comprehensive Cancer Center
NCT05012176
An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information
Fred Hutchinson Cancer Center
NCT06193070
Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer
Wake Forest University Health Sciences
NCT03505671
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
M.D. Anderson Cancer Center
NCT03620201
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
NCT03207529
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
NCT03774472
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT04205903
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 23 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Anatomic Stage III Breast Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anatomic Stage III Breast Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anatomic Stage III Breast Cancer AJCC v8 page
85 registered trials, 48 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 48 Anatomic Stage III Breast Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Anatomic Stage III Breast Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anatomic Stage III Breast Cancer AJCC v8 condition card totals 85 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.